Abstract Methods
Introduction
The first genetic disorders amenable to gene transfer-based treatment will be monofactorial diseases. The vast array oftarget tissues translates the need for the development of appropriate, efficient gene transfer vehicles. The ability of retroviruses to integrate into the host genome has led to their use in ex vivo treatment protocols. Because those cell types capable of withstanding extraction, in vitro manipulation, and, finally, reimplantation are quite limited, other strategies need to be explored. Furthermore, the requirement retroviruses have for host cell proliferation constitutes an important drawback of such vectors and limits their applicability. Many targets relevant to human disease (liver, lung, muscle, neurons) will require other means of gene transfer.
Efficient and long-term expression of genes adenovirally transduced has recently been reported in hepatocytes and bronchial epithelium of animals (1) (2) (3) , showing that the adenoviral vector is capable of transferring genes to nondividing or slowly proliferating cells. To investigate other potential targets for recombinant adenoviral vectors, we have constructed a recombinant adenovirus expressing a nuclearly targeted reporter enzyme (Ad.RSV3gal). The rapid in situ detection of the nuclearly targeted f3-galactosidase allows an unambiguous and precise appreciation of adenoviral-mediated gene transfer (4, 5 were incubated overnight at 30°C in X-gal solution (2 mM) (6). Whole specimens were flash frozen in isopentane in liquid nitrogen and mounted in OCT compound (Miles Laboratories Inc., Naperville, IL) for cryosectioning. Sections (10 Mm thick) were fixed 10 min in p-formaldehyde as described for organs, rinsed, and incubated with X-gal substrate. Sections were then counterstained with hematoxylin and eosin according to standard methods. Muscle was dissociated after whole organ staining to obtain isolated myofibers that were then counterstained with hematoxylin and eosin. Urine and fecal matter were collected at 2 h or 22 d after iv injection and exposed to 293 cells. After 24 h of incubation at 37°C the cells were fixed and stained with X-gal solution. DNA analysis of animals. The heart, lung, liver, and quadricep muscle from mice iv-injected with the recombinant adenovirus Ad.RSVBgal were minced into liquid N2 and ground with a mortar and pestle. Total cellular DNA was prepared as described (10) and 10Mg of either undigested or HindIII-digested DNA was subjected to electrophoresis in a 0.8% agarose gel. Southern blot analyses (Fig. 4 A) were performed using either a SalI-BamHI fragment containing LacZ from pGEM-nlsLacZ (6), or a fragment from the pAd.RSV[3gal plasmid containing the RSV promoter and the upstream adenovirus sequences (Fig. 4 B) to screen for the presence of the recombinant adenovirus. Expression ofthe transferred gene in both cardiac and skeletal muscle was found to be remarkably stable since monthly killed injected animals displayed jl-galactosidase activity in these tissues throughout the 12-mo period of the experiment. Importantly, gene expression was sustained, although the proportion ofblue cells in these muscle tissues seemed to decrease after the 10th month after injection.
Analysis of isolated fibers demonstrates the extent of dissemination of the transferred gene. A single fiber can show multiple "centers of expression" (Fig. 3) . Each consists of a darkly stained central nucleus surrounded by nuclei forming a gradient ofblue. These centers most probably result from independent local infections by the adenoviral vector. The number ofcolored nuclei in any one cluster was found to vary from 10 to 60. The use of a nuclearly targeted marker is informative as to the degree of infection of multinucleated cells of this morphology.
Expression of the transferred gene in mice injected as adults. As to the distribution of the virus, results similar to those obtained in mice injected as newborns were found after intravenous inoculation ofadults. It is apparent, however, that the injection of 109 pfu of virus leads to less efficient gene transfer in the larger adult mice. Intramuscular injections were also performed and histochemical staining at 21 days after injection revealed that the infection was circumscribed to the point of injection, as fibers with blue nuclei could only be detected within a 1-cm area. Moreover, the absence ofblue staining in other tissues (lung, liver, intestine) reveals a very limited diffusion of the virus when the intramuscular route is chosen.
Status of the viral DNA. Southern blot analysis of DNA from different tissues of an experimental animal indicates the presence ofthe adenovirus genome in a wide variety of organs (Fig. 4 A) . The detection ofa DNA fiagment corresponding to the left end ofthe recombinant viral genome indicates that the viral DNA is present as a linear form in the tissues infected 10 d previously (Fig. 4 B) . Moreover, the detection of a unique and intense band corresponding to 35.5 kb at 3 mo after injection reveals that the viral DNA remains extrachromosomal (Fig. 5) . The absence ofa detectable smear rules out the possibility that integration events occurred with high frequency. Clearly, the sensitivity of the Southern blot does not allow a fair appreciation ofgene transfer as does the in situ detection ofthe fl-galactosidase activity. In this respect, it is reasonable that the estimation of a 0.2% transfer to the heart (based on staining) is compatible with the difference in intensity seen with the transgenic mouse DNA control (which harbors one copy of a LacZ gene per cell) (Fig. 4 A) . The incapacity to detect a band in the heart 12 mo after injection is in agreement with the decrease in the number of blue cells observed at this time.
Discussion
Gene therapy relevant to muscular diseases is especially hindered by the unsolved problem of the direct widespread transfer of a gene to the related tissues. Attempts to modify muscle tissue have centered around fusion of implanted myocytes with host muscle (1 1, 12) or injection of DNA (13) (14) (15) . may, nevertheless, have too many drawbacks for it to be applicable to the treatment ofdisease. As the migratory capacities of precursor cells are restricted to a few millimeters, cell implantation would necessitate millions of injections during hours of anesthesia. Inevitably, immunological problems would be encountered, as with any graft. Furthermore, large scale requirements for human myogenic cells constitute a practical limitation. In addition, the treatment of Duchenne muscular dystrophy (DMD) not only calls for therapy for skeletal muscles, but for myocardial cells too. It is difficult to envisage cell therapy as a means to provide relief to such an array of diseased cells. The concept of somatic gene therapy will more than likely provide the most promising solution in the future. Importantly, its scope goes beyond the treatment of muscle disease, since it is applicable to a large number ofgenetic disorders. The direct introduction ofpurified nucleic acids into various organs in vivo is attractive due to its simplicity, but again, practical obstacles may limit its development. Furthermore, the resultant gene expression in muscle remains localized to the point of injection of DNA (13) and seems to be quite limited in duration, particularly in cardiac muscle (14) . Interestingly, all other organs tested proved to be nonreceptive to DNA transfection. Thus, a method allowing a more widespread distribution of stable gene expression would be of invaluable importance to gene therapy in general.
The present report demonstrating the feasibility ofadenovirus-mediated direct in vivo gene transfer into myocytes ofmice has serious implications for treatment of muscular disorders, including heart diseases. Importantly, adenovirus can carry tissue-specific promoters, consequently restricting the actual sites of expression of the exogenous gene (16, 17 (Fig. 2 E) , but also occasionally in a few epithelial cells of this organ (data not shown).
